Tokyo, Japan, February 16, 2015 --- Teijin Pharma Limited ,the core company of the Teijin Group’s medical and pharmaceutical business, announced today that Japan's Ministry of Health, Labour and Welfare approved Teijin Pharma's novel expectorant drug formulated as a reduced-size tablet, Mucosolvan L tablet 45 mg (ambroxol hydrochloride), on February 16. Teijin Pharma plans to launch the tablet this summer.
Mucosolvan L capsule and Mucosolvan L tablet
This sustained-release tablet measures just 7.5 mm x 6 mm, which is smaller and more easily swallowed than conventional once-daily expectorant drugs. It contains the same active ingredient as Mucosolvan L capsule 45mg, a once-daily product now on the market, and expected to have the same effect, especially when administered after dinner for the treatment of productive sputum the following morning.
The medical field has high expectations for the tablet’s reduced size, as expectorants are often taken with other drugs. The tablet is also expected to be effective for treating productive sputum in the morning.
Mucosolvan, an ethical drug for patients with respiratory diseases, such as bronchitis and chronic obstructive pulmonary disease (COPD), helps to reduce sputum adhesion to the trachea and the bronchus. More than 60% of patients with chronic respiratory diseases such as COPD suffer productive sputum in the morning.
Mucosolvan, which has been licensed by Boehringer Ingelheim and on sale since 1984, responds to the needs of those who prefer a formulation other than a liquid, syrup or once-daily capsule.
About the Teijin Group
Teijin (TSE: 3401) is a technology-driven global group offering advanced solutions in the areas of sustainable transportation, information and electronics, safety and protection, environment and energy, and healthcare. Its main fields of operation are high-performance fibers such as aramid, carbon fibers & composites, healthcare, films, resin & plastic processing, polyester fibers, products converting and IT. The group has some 150 companies and around 16,000 employees spread out over 20 countries worldwide. It posted consolidated sales of JPY784.4 billion (USD 7.7 billion) and total assets of JPY 768.4 billion (USD 7.5 billion) in the fiscal year ending March 31, 2014.
+81 3 3506 4055
Information in the press releases is current on the date of the announcement.
It is subject to change without prior notice.